These findings unveil novel molecular mechanisms underlying the regulation of cancer immunity and IFN‐γ signaling, offering insights into a promising therapeutic strategy to enhance the effectiveness of immune checkpoint therapy. The gene discussed is IFNG; the disease is cancer.